Online inquiry

IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13395MR)

This product GTTS-WQ13395MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13395MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5744MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ228MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ2483MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ3792MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ661MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ15810MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ15310MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ12280MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW